Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

35.78 +0.52 (+1.48%)
Delayed Quote Updated: 10:03 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
Via AB Newswire
Topics Intellectual Property
News headline image
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Third Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated... 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.